🔴 Alzamend Neuro is trading 5.7% down today, extending losses amid biotech sector pressure and geopolitical tensions

Alzamend Neuro is trading 5.7% down at $1.09 in pre-market, extending weakness from the prior session amid broader biotech-sector pressure.

• Shares fell approximately 5.9% on July 13, 2026, driven by risk-off sentiment tied to escalating U.S.–Iran geopolitical tensions.
• No new company-specific news, regulatory filings, or analyst actions have been reported to explain the recent downward movement.
• The current pre-market decline reflects continued cautious trading within a fragile macroeconomic and risk-averse environment.